Research Article
Emergency Use of Tocilizumab in Moderate and Severe COVID-19 Patients over the Prevaccination Stage during the Pandemic in Mexico
Table 3
Mortality-related quantitative characteristics of the population.
| Characteristic | Alive | Death | value |
| Onset of the symptoms | 8.25 ± 3.884 | 9 ± 4.493 | 0.47 | Age | 47.6 ± 11.32 | 54.45 ± 12.32 | 0.025 | BMI | 29.1 ± 4.91 | 29.43 ± 5.34 | 0.824 | SaO2% without O2 | 74.33 ± 13.98 | 71.55 ± 10.34 | 0.40 | SaO2% with O2 | 87.75 ± 9.39 | 85.64 ± 5.84 | 0.331 | Heart rate | 91.35 ± 16.04 | 94.36 ± 18.16 | 0.487 | Respiratory rate | 23.54 ± 4.32 | 24.73 ± 5.17 | 0.321 | Leucocytes | 9.35 ± 4.97 | 12.37 ± 3.27 | 0.012 | Neutrophils | 8.05 ± 4.91 | 11.13 ± 3.20 | 0.009 | Lymphocytes | 0.93 ± 0.52 | 0.70 ± 0.42 | 0.075 | Glucose | 137.43 ± 73.57 | 184.40 ± 144.84 | 0.163 | ALT | 66.01 ± 95.00 | 43.04 ± 38.63 | 0.327 | AST | 73.73 ± 148.66 | 51.39 ± 58.29 | 0.529 | LDH | 487.88 ± 327.41 | 505.31 ± 182.31 | 0.844 | Total bilirubin | 0.61 ± 0.38 | 0.69 ± 0.27 | 0.474 | CK | 105.65 ± 111.02 | 122.15 ± 84.85 | 0.706 | Glomerular filtration rate | 94.80 ± 25.50 | 75.10 ± 35.79 | 0.030 | Fibrinogen | 1513 ± 2803.29 | 862.80 ± 453.92 | 0.617 | PCR | 18.04 ± 10.23 | 26.68 ± 13.16 | 0.012 |
|
|